

## VERÖFFENTLICHUNGEN

### ORIGINAL PUBLIKATIONEN MIT GUTACHTERSYSTEM

1. **Grünblatt E.**, Mandel S., Berkuzki T. and Youdim M.B.H. (1999) Apomorphine protects against MPTP induced neurotoxicity in mice *Mov. Disord.* 14: 612-618.
2. **Grünblatt E.**, Mandel S., Maor G., and Youdim M.B.H. (2001) Effects of R-apomorphine and S-apomorphine on MPTP-induced striatal dopamine neuronal loss. *J. Neurochem.* 77(1): 146-156.
3. **Grünblatt E.**, Mandel S., Maor G., and Youdim M.B.H. (2001) Gene expression analysis in MPTP model of Parkinson's disease using cDNA microarray. *J. Neurochem.* 78(1): 1-12.
4. Mandel S., **Grünblatt E.**, Maor G. and Youdim M.B.H. (2002) Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. *Neurochem Res.* 2002 Oct; 27(10):1231-43.
5. **Grünblatt E.**, Hoyer S., Riederer P. (2004) Gene expression profile in streptozotocin rat model for sporadic Alzheimer's disease. *J. Neural Transm.* 111(3): 367-386.
6. **Grünblatt E.**, Mandel S., Hirsch J.J., Zeligson S., Amariglio N., Rechavi G, Li J., Ravid R., Roggendorf W., Riederer P., Youdim M.B.H. (2004) Genomic profiling of Parkinsonian substantia nigra pars compacta; Alterations in Ubiquitin-proteasome, heat shock protein, iron regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. *J. Neural Transm.* 111(12):1543-73.
7. **Grünblatt E.**, Schlößer R, Fischer P, Fischer MO, Li J, Koutsilieri E, Wichart I, Sterba N, Rujescu D, Möller HJ, Adamczyk W, Dittrich B, Müller F, Oberegger K, Gatterer G, Jellinger KJ, Mostafaie N, Jungwirth S, Huber K, Tragl KH, Danielczyk W, Riederer P (2005) Oxidative stress related factors related markers in the "VITA" and the Centenarian projects. *Neurobiol. Aging.* 26(4): 429-438.
8. Scheller C, Sopper S, Jenuwein M, Neuen-Jacob E, Tatschner T, Stahl-Hennig C, **Grünblatt E.**, ter Meulen V, Riederer P, Koutsilieri E (2005) Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkeys due to microglia activation. *J. Neurochem.* 95(2):377-87.

### IN VORBEREITUNG

1. Mehler-Wex C.\*, **Grünblatt E.\***, Zeiske S, Gille G, Rausch D., Warnke A , Gerlach M (2005) Microarray analyses reveals distinct gene expression patterns in the mouse cortex following chronic neuroleptic and stimulant treatment: implications for body weight changes. In Vorbereitung. (\* Both authors contributed equally).
2. **Grünblatt E.**, Koutsilieri E, Hoyer S, Riederer P (2005) Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat. In Vorbereitung.
3. Scheller C, Knöferle J, Ullrich A, Prottengeier J, Racek T, Lamla S, **Grünblatt E.**, Sopper S, Jassoy C, Rethwilm A, Koutsilieri E (2005) Reciprocal regulation

of CD95-induced apoptosis and necrosis in human T lymphocytes. In Vorbereitung.

4. Luckhaus C, Spiegler C, Ibach B, Kick C, Eichhammer P, Hajak G, Fischer P, Wichart I, Sterba N, Gatterer G, Rainer M, Jungwirth S, Huber K, Tragl KH, **Grünblatt E**, Riederer P, Sand P (2005) A 5'UTR variant in the estrogen sulfotransferase (STE) gene is a candidate risk modifier for Alzheimer's disease in women, In Vorbereitung.
5. **Grünblatt E**, Zander N, Hofmann M, Li J, Riederer P (2005) Gene expression profile in different stages of sporadic Alzheimer's disease compared to Parkinson's disease. In Vorbereitung.
6. Jacob CP, Koutsilieri E, Zander N, Neuen-Jacob E, Hofmann M, Bartl J, Ravid R, Roggendorf W, Riederer P, **Grünblatt E** (2005) Glutamate in sporadic Alzheimer's Disease. In Vorbereitung.

### INVITED REVIEW

1. Mandel S., **Grünblatt E.**, Riederer P., Gerlach M., Levites Y., Youdim M.B.H. (2003) Neuroprotective Strategies in Parkinson's disease: An Update on Progress. *CNS Drug*. 17(10): 729-762.
2. **Grünblatt E.** (2004) The benefits of microarrays as a tool for studying neuropsychiatric disorders. *Drugs of Today*. 40(2): 147-156.
3. Wiltfang J, Lewczuk P, Riederer P, **Grünblatt E**, Hock C, Scheltens P, Hampel H, Vanderstichele H, Iqbal K, Galasko D, Lannfelt L, Otto M, Esselmann H, Henkel AW, Kornhuber J, Blennow K (2005) Consensus paper of the WFSBP Task Force on biological markers of dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia. *World J. Biol. Psychiatry*. 6 (2): 69-84.

### KONFERENZPUBLIKATIONEN

1. **Grünblatt E.**, Mandel S., Gassen, M. and Youdim M.B.H. (1999). Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. *J. Neural Transm. (Suppl)* 55: 57-70.
2. Youdim M.B.H., **Grünblatt E.** and Mandel S. (1999) The pivotal role of iron in NF-kB activation and nigro-striatal dopaminergic neurodegeneration; prospects for neuroprotection in Parkinson's Disease with iron chelators. *Ann N.Y. Acad. Sci.* 890:7-25.
3. **Grünblatt E.**, Mandel S., and Youdim M.B.H. (2000). Neuroprotective strategies in Parkinson's disease using the animal models of 6-hydroxydopamine and MPTP. *Ann. N.Y. Acad. Sci.*, 899: 262-273.
4. **Grünblatt E.**, Mandel S., and Youdim M.B.H. (2000). MPTP and 6-OHDA-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies. *J. Neurol.*, 247 [Suppl. 2]: II/95-II/102.

5. Youdim M.B.H., Gassen M., Gross A., Mandel S. and **Grünblatt E.** (2000) Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist: apomorphine. *J. Neural. Transm. Suppl.* 58: 83-96.
6. Mandel S., **Grünblatt E.** and Youdim M.B.H. (2000) cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. *J. Neural. Transm. Suppl.* 60: 117-124.
7. Youdim M.B.H., **Grünblatt E.**, Royak Y. and Mandel S. (2001). Drugs to prevent cell death in Parkinson's disease: Neuroprotection against oxidative stress and inflammatory gene expressions. *Adv. Neurol.* 86: 115-124.
8. Koutsilieri E., Scheller C., **Grünblatt E.**, Nara K., Li J., Riederer P. (2002) Free radicals in Parkinson's disease. *J. Neurol.* 249(Suppl 2): II/1-II/5.
9. Youdim MB, **Grünblatt E.**, Levites Y, Maor G, Mandel S. (2002) Early and late molecular events in neurodegeneration and neuroprotection in Parkinson's disease MPTP model as assessed by cDNA microarray; the role of iron. *Neurotox Res* 4(7-8): 679-689.
10. **Grünblatt E.**, Schlößer R., Gerlach M., Riederer P. (2003) Preclinical versus clinical neuroprotection. *Adv. Neurol.* 91: 309-328.
11. Mandel S, **Grünblatt E.**, Riederer P, Youdim MB. (2003) Genes and oxidative stress in parkinsonism: cDNA microarray studies. *Adv. Neurol.* 91: 123-32.
12. Riederer P., Danielczyk W., **Grünblatt E.** (2004) Monoamine-oxidase-B inhibition in Alzheimer's disease. *Neurotoxicology.* 25 (1-2): 271-277.
13. **Grünblatt E.**, Mandel S, Li J, Jacob-Hirsch J, Zeligson S, Amariglio N, Rechavi G, Ravid R, Arzberger T, Roggendorf W, Youdim MBH, Riederer P (2005) Genexpressionanalysen von Substantia-nigra-Gewebe Parkinson-Kranker. *MedReport.* 3 (29. Jahrgang): 4
14. Mandel S, **Grünblatt E.**, Riederer P, Amariglio N, Jacob-Hirsch J, Rechavi G, Youdim MB. (2005) Gene Expression Profiling of Sporadic Parkinson's Disease Substantia Nigra Pars Compacta Reveals Impairment of Ubiquitin-Proteasome Subunits, SKP1A, Aldehyde Dehydrogenase, and Chaperone HSC-70. *Ann N Y Acad Sci.* 1053:356-75.

## BÜCHER

1. Mandel S., **Grünblatt E.** and Youdim M.B.H. (1999). Therapeutic potential of radical scavengers in Parkinson's disease. *In: Free Radicals in Brain Pathophysiology.* (Poli, G. Cadenas, E., Packer, L., Eds), Marcel Decker press, NY, Chapter. 23, p. 487-500.
2. **Grünblatt E.**, Mandel S., Yona Royak and Youdim, M.B.H. (2001). The contributions of intracellular non-haem iron, NFkB activation and inflammatory responses to neurodegeneration in Parkinson's disease; Prospects for neuroprotection. *In: Neurotoxic factors in Parkinson's disease and related disorders.* (Michael A. Collins, Alexander Storch, eds.), Kluwer Academic/Plenum publishers, NY, in press.

3. Mandel, S., **Grünblatt, E.**, and Youdim, M. B. H. (2000) cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for Parkinson's disease. Pages 117-125 (P. Riederer, D. B. Calne, R. Horowski, Y. Mizuno, C. W. Olanow, W. Poewe, and M. B. H. Youdim, Eds.), *Advances in Neurodegeneration Diseases*, Vol. 8. Springer Medicine, Wien New York.
4. Kettler R., Borroni E., Cesura A., **Grünblatt E.**, Jorga K., Richards J.G., Riederer P. and Da Prada M. (2002) Monoamine-oxidase-hemmer: Neurobiochemie, Wirkmechanismus. Pages 474-488 (Riederer P., Laux G. and Pödlinger W., Eds.), *Neuro-Psychopharmaka. Ein Therapie-Handbuch. Band 3: Antidepressiva, Phasenprophylaktika und Stimmungsstabilisierer*. Zweite, neubearbeitete Auflage, Springer-Verlag, Wien, Austria.

## ABSTRAKTE

### VORTRÄGE

1. **Grünblatt E.**, Mandel S., Berkuzki T. and Youdim M.B.H. Protective effect of Apomorphine against MPTP induced neurotoxicity in C57-BL mice. *Neuroscience Lett. Suppl* 51, S17. Seventh annual meeting of the Israeli Society for Neuroscience, Eilat, Israel, December 6-8, 1998.
2. **Grünblatt E.**, Mandel S. and Youdim M.B.H. Alteration of inflammatory and oxidative stress gene expression in MPTP mice model; Protection by apomorphine. Eighth annual meeting of the Israeli Society for Neuroscience, Eilat, Israel, November 28, 1999.
3. **Grünblatt E.**, Riederer P. Application of gene-chip technology to study differential gene expression in human dementia. 3rd Forum of European Neuroscience, Paris, France, July 12-17, 2002.
4. **Grünblatt E.** Gene chips in a model of Alzheimer's disease. 7<sup>th</sup> Congress of the European Federation of Neurological Societies, Helsinki, Finland, August 30-September 2, 2003.
5. **Grünblatt E.**, Fischer P, Schlößer R, Hupp E, Fischer MO, Li J, Bambula M, Koutsilieri E, Wichart I, Sterba N, Rujescu D, Möller HJ, Adamscy W, Dittrich B, Müller F, Oberegger K, Gatterer G, Jellinger KJ, Mostafaie N, Jungwirth S, Danielczyk W, Huber K, Tragl KH, Riederer P. Molecular markers in the Vienna-Transdanube-Aging "VITA" and the Centenarian projects. 5<sup>th</sup> Hamburg Conference on Alzheimer's disease, Hamburg, Germany, November 21-22, 2003.
6. **Grünblatt E.**, Hoyer S., Riederer P. Genetic aspects of Alzheimer's disease (2003). Regional symposium WFSBP (The world federation of societies of biological psychiatry), Bruges, Belgian, December 11-13, 2003. *Eur. Arch. Psychiatry Clinical Neurosci.* 253 (Suppl. 1): I/6.
7. **Grünblatt E.**, Mandel S., Li J., Amariglo N., Yaakov J., Rechavi G, Roggendorf W., Hoyer S., Youdim M.B.H., Riederer P. Genes and oxidative stress (2004). 17<sup>th</sup> Congress of the European College of Neuropsychopharmacology, Stockholm, Sweden, 9-13 October, 2004. *J. Eur. College Neuropsychopharm.* 14 (Suppl. 3) S168-S169.

8. **Grünblatt E.**, Li J., Arzberger T., Neumann M., Kneitz S., Ravid R., Roggendorf W., Riederer P. (2004) Regional Gene-Chip-Array study in sporadic Alzheimer's disease patients. 6<sup>th</sup> Drei-Länder-Symposium für Biologische Psychiatrie. Bern, Switzerland, 21-24 October, 2004. Eur. Arch. Psych. Clinical Neurosc. 254 (Suppl. 1) I/18.
9. **Grünblatt E**, Mandel S, Li J, Jacob-Hirsch J, Zeligson S, Amariglio N, Rechavi G, Ravid R, Arzberger T, Roggendorf W, Youdim MBH, Riederer P (2005) Genexpressionanalysen von Substantia-nigra-Gewebe Parkinson-Kranker. 4<sup>th</sup> Deutscher Parkinson-Kongress, Frankfurt am Main, Germany, 3-5<sup>th</sup> March, 2005. Aktuelle Neurologie. 32 (Suppl. S1): S14
10. **Grünblatt E** (2005) Gene expression study techniques in post-mortem tissue and blood sample. 16<sup>th</sup> International Congress on Parkinson's Disease and Related Disorders, June 5-9, Berlin, Germany. Parkinsonism & Related Disorders 11 (Suppl. 2) p86.
11. **Grünblatt E**, Fischer P, Bartl J, Miryame H, Jungwirth S, Tragl KH, Riederer P (2005) Choline acetyltransferase and dopamine D4 receptor association in the "VITA" project. 8<sup>th</sup> World Congress of Biological Psychiatry. June 28<sup>th</sup>-July 3<sup>rd</sup>, Vienna, Austria. The world J. Biol. Psychiat. 6(Suppl. 1) p. 133.

#### POSTERPRÄSENTATION

12. **Grünblatt E.**, Mandel S., Berkuzki T. and Youdim M.B.H. Transgenic mice models for oxidative- stress mediated neurodegeneration. The 4<sup>th</sup> Congress of the European Society for Clinical Neuropharmacology, Eilat, Israel, 1-4 December 1997.
13. **Grünblatt E.**, Mandel S., Berkuzki T. and Youdim M.B.H. Apomorphine, a protective drug in MPTP-induced neurotoxicity. XIII International Congress on Parkinson Disease, Vancouver, Canada, July 24-28, 1999.
14. **Grünblatt E.**, Mandel S., Maor G. and Youdim M.B.H. Does S(+)-apomorphine has similar neuroprotective properties in vivo as R(-)-apomorphine? 6<sup>th</sup> international congress of Parkinson's disease and movement disorders, Barcelona, Spain, June 11-15, 2000.
15. **Grünblatt E.**, Mandel S., Maor G. and Youdim M.B.H. Alterations of oxidative-stress and inflammatory gene expression in MPTP-induced neurotoxicity and their prevention by R-apomorphine. 6<sup>th</sup> international congress of Parkinson's disease and movement disorders, Barcelona, Spain, June 11-15, 2000.
16. **Grünblatt E.**, Mandel S., Maor G. and Youdim M.B.H. Early and late gene changes in MPTP mice model of Parkinson's disease. German Parkinson Society congress, Bochum, Germany, March 7-11, 2001.
17. **Grünblatt E.**, Hoyer S. and Riederer P. (2002) Differential gene expression in streptozotocin rat model for sporadic Alzheimer's disease. Neurobiology of Aging. 23(1 Suppl): S331. The 8<sup>th</sup> International Conference on Alzheimer's disease and related disorders, Alzheimer's Association. Stockholm, Sweden, July 20-25, 2002.
18. Hupp E, Wichart I, Sterba N, Adamczyk W, Dittrich B, Müller F, Oberegger K, Gatterer G, Jellinger KA, Danielczyk W, Fischer P, Tragl KH, **Grünblatt E**, Riederer P. (2002) Neurotrophic factors related markers investigated in the Vienna-Transdanube-Aging "VITA\*" project: The role of Ciliary-neurotrophic

- factor (CNTF) nullmutation and Brain-derived neurotrophic factor (BDNF) plasma level in Alzheimer's disease. *Neurobiology of Aging*. 23(1 Suppl): S386. The 8<sup>th</sup> International Conference on Alzheimer's disease and related disorders, Alzheimer's Association. Stockholm, Sweden, July 20-25, 2002.
19. Riederer P, Schlößer R, Koutsilieri E, Wichart I, Sterba N, Adamcyk W, Dittrich B, Müller F, Oberegger K, Gatterer G, Jellinger KA, Danielczyk W, Fischer P, Tragl KH, **Grünblatt E.** (2002) Oxidative stress related markers investigated in the Vienna-Transdanube –Aging “VITA\*” Project: The role of platelet monoamine oxidase (MAO-B), erythrocyte superoxide dismutase (SOD) and lactoferrin in Alzheimer's disease. *Neurobiology of Aging*. 23(1 Suppl): S387. The 8<sup>th</sup> International Conference on Alzheimer's disease and related disorders, Alzheimer's Association. Stockholm, Sweden, July 20-25, 2002.
  20. Hupp E, Wichart I, Sterba N, Adamcyk W, Dittrich B, Müller F, Oberegger K, Gatterer G, Jellinger KA, Danielczyk W, Fischer P, Tragl KH, **Grünblatt E,** Riederer P. (2002) Neurotrophic factors related markers investigated in the Vienna-Transdanube-Aging “VITA\*” project: The role of Ciliary-neurotrophic factor (CNTF) nullmutation and Brain-derived neurotrophic factor (BDNF) plasma level in Alzheimer's disease. *European Archives of Psychiatry and Clinical Neuroscience*. 252 (Suppl. 1) P237. 8th Congress of the German Society for Biological Psychiatry. 10-12 October 2002, Düsseldorf, Germany
  21. Riederer P, Schlößer R, Koutsilieri E, Wichart I, Sterba N, Adamcyk W, Dittrich B, Müller F, Oberegger K, Gatterer G, Jellinger KA, Danielczyk W, Fischer P, Tragl KH, **Grünblatt E.** (2002) Oxidative stress related markers investigated in the Vienna-Transdanube –Aging “VITA\*” project: The role of platelet monoamine oxidase (MAO-B), erythrocyte superoxide dismutase (SOD) and lactoferrin in Alzheimer's disease. *European Archives of Psychiatry and Clinical Neuroscience*. 252 (Suppl. 1) P238. 8th Congress of the German Society for Biological Psychiatry. 10-12 October 2002, Düsseldorf, Germany.

#### TEILNAHME AN POSTER / VORTRÄGE

1. Th. Rohe, **E. Grünblatt,** F. Nagel, N. Eisenreich . NIR-Transmission Spectroscopy on Propellants and Explosives, 27th International Annual Conference of ICT, Energetic Materials - Technology, Manufacturing and Processing, Karlsruhe, Germany, pp. 85, June 25 - June 28, 1996.
2. Youdim M.B.H., Mandel S., **Grünblatt E.,** Berkuzki T. and Gassen M. What is new in neuroprotection with radical scavengers in animal models of Parkinson's disease? The 10<sup>th</sup> Rappaport Symposium, Understanding Parkinson's Disease, Zichron Yaakov, Israel, 10-13 May 1998.
3. Mandel S., **Grünblatt E.,** Berkuzki T., Del Canho S. and Youdim M.B.H. Transgenic mouse models for oxidative-stress mediated neurodegeneration. *Neuroscience Lett*. Suppl 51, S27. Seventh annual meeting of the Israel society for neurosciences, Eilat, Israel, December 6-8, 1998.
4. Mandel S., **Grünblatt E.** and Youdim M.B.H. Models for oxidative-stress mediated neurodegeneration. XIII international congress on Parkinson's disease, Vancouver, Canada, July 24-28, 1999.

5. Moussa B.H. Youdim, **Edna Grünblatt**, Yona Royak and Silvia Mandel. ISN Satellite meeting on "Neurotoxic Factors in Parkinson's disease and Related Disorders", Ulm, Germany, August 6-7, 1999.
6. Mandel S., **Grünblatt E.** and Youdim M.B.H. Transgenic mice overexpressing APP are more sensitive to neurotoxicity by MPTP. Eighth annual meeting of the Israeli Society for Neuroscience, Eilat, Israel, November 28, 1999.
7. Mandel S., **Grünblatt E.** and Youdim M.B.H. Transgenic mice models for oxidative-stress mediated neurodegeneration. The annual meeting of the Israel society for oxygen and free radical research and the 13<sup>th</sup> Rappaport Symposium, Haifa, Israel, December 5, 1999.
8. Mandel S., **Grünblatt E.** and Youdim M.B.H. Gene products in MPTP induced neurodegeneration. 8<sup>th</sup> international winter conference on neurodegeneration, Tegernsee, Germany, February 9-13, 2000.
9. Mandel S., **Grünblatt E.**, Royak-Levites Y., Maor G. and Youdim M.B.H. Molecular biology of MPTP and 6-OHDA-induced parkinsonism in animals. 14<sup>th</sup> Rappaport symposium: "The Molecular Basis of Neuropsychiatric Diseases", Haifa, Israel, April 11-13, 2000.
10. Luckhaus C, Spiegler C, Sand P, Jacob C, Wichard I, Fischer P, Danielczyk W, Sterba N, Gatterer G, Tragl KH, **Grünblatt E.**, Beckmann H, Riederer P. (2002) Estrogen receptor beta (ERB) polymorphisms in Alzheimer's disease and old age dementia. *Neurobiology of Aging*. 23(1 Suppl): S387. The 8<sup>th</sup> International Conference on Alzheimer's disease and related disorders, Alzheimer's Association. Stockholm, Sweden, July 20-25, 2002.
11. Mehler-Wex C, Zeiske S, **Grünblatt E**, Gille G, Rausch D, Warnke A, Gerlach M (2003) Mouse brain gene expression changes after chronic treatment with neuroleptics. *European Child & Adolescent Psychiatry*. 12 (Suppl. 2): I/153 (N353). 12<sup>th</sup> International congress of the European Society for Child and Adolescent Psychiatry. 18<sup>th</sup> September-1<sup>st</sup> October 2003, Paris, France.
12. Mehler-Wex C, Zeiske S, **Grünblatt E**, Gille G, Rausch D, Warnke A, Gerlach M (2004) Mouse brain gene expression changes after chronic treatment with psychotropic drugs. 16<sup>th</sup> World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions. 22-26 2004, Berlin, Germany.
13. Youdim MBH, **Grünblatt E**, Riederer P, Mandel S (2005) Convergence of sporadic with familial Parkinson's disease; Failure of the ubiquitin-proteasome system as identified by genomic and proteomic profiling. 16<sup>th</sup> International Congress on Parkinson's Disease and Related Disorders, June 5-9, Berlin, Germany. *Parkinsonism & Related Disorders* 11 (Supl. 2) p86.
14. Li J, Double K, Gerlach M, Riederer P. **Grünblatt E** (1995) The effects of neuromelanin and synthetic dopamine melanin on oxidative stress related gene expression in cell lines. 16<sup>th</sup> International Congress on Parkinson's Disease and Related Disorders, June 5-9, Berlin, Germany. *Parkinsonism & Related Disorders* 11 (Supl. 2) p86.
15. Jacob C, **Grünblatt E**, Riederer P (2005) Glutamate in sporadic Alzheimer disease. 8<sup>th</sup> World Congress of Biological Psychiatry. June 28<sup>th</sup>-July 3<sup>rd</sup>, Vienna, Austria. *The world J. Biol. Psychiat.* 6(Suppl. 1) p. 44.